ArticleOncotarget2016
Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Urine and Serum miRNA Signatures for the Non-Invasive Diagnosis of Adenomyosis: A Machine Learning-Based Pilot Study.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic Potential of Serum Circulating miRNAs for Endometriosis in Patients with Chronic Pelvic Pain.Journal of clinical medicine · 2025Article
- Let-7a microRNA modulates caspase-3-dependent apoptosis in melanoma cells treated with dabrafenib and trametinib combination.Irish journal of medical science · 2025Article
- The Role of microRNAs in Lung Cancer: Mechanisms, Diagnostics and Therapeutic Potential.International journal of molecular sciences · 2025Review
- A Glimmer of Hope for Patients with a T3 Transformation Zone: miRNAs Are Potential Biomarkers for Cervical Dysplasia.Diagnostics (Basel, Switzerland) · 2023Article
- Prognostic gene biomarker identification in liver cancer by data mining.American journal of translational research · 2021Article
- Identification of prognostic gene biomarkers for metastatic skin cancer using data mining.Biomedical reports · 2020Article
- MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip.BMC medical genomics · 2020Article
- Identification of 5 Gene Signatures in Survival Prediction for Patients with Lung Squamous Cell Carcinoma Based on Integrated Multiomics Data Analysis.BioMed research international · 2020Article
- miR‑146a‑5p targets TCSF and influences cell growth and apoptosis to repress NSCLC progression.Oncology reports · 2019Article
- Article
- Construction and validation of a seven-microRNA signature as a prognostic tool for lung squamous cell carcinoma.Cancer management and research · 2019Article
- A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma.Cancer biomarkers : section A of Disease markers · 2019Article
- Genome-wide analysis of NGS data to compile cancer-specific panels of miRNA biomarkers.PloS one · 2018Article
- Diagnostic and prognostic value of microRNA-628 for cancers.Journal of Cancer · 2018Article
- Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma.Cancer management and research · 2018Article
- MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer.Cell proliferation · 2017Review
- Comprehensive analysis of a novel four-lncRNA signature as a prognostic biomarker for human gastric cancer.Oncotarget · 2017Article
- Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpecific biomarkers for outcome prediction of lung squamous cell carcinoma (LUSC) are still lacking. This study assessed the prognostic value of differentially expressed miRNAs of LUSC patients.
resultsTwelve of the 133 most significantly altered miRNAs were associated with overall survival (OS) across different clinical subclasses of the Cancer Genome Atlas (TCGA) LUSC cohort. A linear prognostic model of seven miRNAs was developed to divide patients into high- and low-risk groups. Patients assigned to the high-risk group exhibited poor OS compared with patients in the low-risk group, which was further validated in the validation cohort and entire LUSC cohort.
methodsMiRNA expression profiles with clinical information of 447 LUSC patients were obtained from TCGA. Most significantly altered miRNAs were identified between tumor and normal samples. Using survival analysis and supervised principal components method, a seven-miRNA signature for prediction of OS of LUSC patients was established. Survival receiver operating characteristic (ROC) analysis was used to assess the performance of survival prediction. The biological relevance of predicted miRNA targets was also analyzed using bioinformatics method.
conclusionsThe current study suggests that seven-miRNA signature may have clinical implications in the outcome prediction of LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.